Foscan
temoporfin · Biolitec Pharma Ltd
AUTHORISED IN THE EUWhat Foscan is used for
Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Foscan
- Active substance
- temoporfin
- Disease area
- Head and Neck Neoplasms; Carcinoma, Squamous Cell
- Medicine group
- Antineoplastic agents
- ATC code
- L01XD05
- Marketing authorisation holder
- Biolitec Pharma Ltd
- Authorised in the EU since
- 2001
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Foscan used for?
Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.
What is the active substance in Foscan?
Foscan contains temoporfin.
Who makes Foscan?
The EU marketing authorisation holder is Biolitec Pharma Ltd.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU